Substance related and addictive disorders

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/65

encourage image

There's no tags or description

Looks like no tags are added yet.

66 Terms

1
New cards

substance use disorder

  • maladaptive pattern fo substance use leading to clinically significant impairment or distress, as manifested by ≥2 occurign within 12 month period

  • mila: 2-3

  • mod: 4-5

  • severe >6


2
New cards

substance use disorder- impaired control criteria

  1. use of larger amnt, for longer than intended

  2. craving

  3. sig tiem spent obtining/using/recovering

  4. repeated attempts to quit/control use


3
New cards

substance use disorder-social impairment criteria

  • social/interpersonal problems related to use

  • neglected major roel to use

  • acitivites given up for use


4
New cards

substance use disorder- cont use despite risk criteria

  • hazaroud use

  • physical/psych problems realted to use


5
New cards

substance use disorder- pharm criteria

  • tolerance

  • withdrawal


6
New cards

use disorder

longitudinal pattern of use despite neg consequences

7
New cards

intoxicaiton

  • reversible sub-specific syndrome encompassing acute effects after use


8
New cards

withdrawal

  • dev of substance specific sx after reduction/cessation


9
New cards

short term benefits of caffiene

  • increased mental alertness

  • improves in vigilance and reaction time

  • improved athletic performance

  • in mod doses, mitigates adverse effects of sleep dep and jet lag on cognitive performance and mental awareness


10
New cards

possible long term benefits of caffeine

  • dose dependent

  • assocaited with reduced risk of parkinson disease, alzheimer disease, alcoholic cirrhosis, and gout


11
New cards

mortality and caffeine

  • modest inverse relationshipo between coffee/tea consumption and all cause mortality


12
New cards

ADE of caffeine

  • high level consumption associated with dhort term aade

    • HA

    • anxiety

    • tremors

    • insomnia

  • chronic users ,less sensitive to adverse behavioral effects

  • long term, associated with GAD and SUD


13
New cards

caffeine intoxicaiton

  • recent consumption of caffeine (>250mg)

  • ≥5 durign or shortly after use

    • restlessness, nervousness, insomnia, flushing, diuresis, GI disturbance, muscel twitching, rambling flow of though and speech, tachy/cardiac arrhythmia, psychomotor agitation


14
New cards

caffeine intoxication >1g

  • can produce ramblign speech, confused thinking, cardiac arrhythmias, marked agitation, tinnitusm and mild visual hallucinations


15
New cards

caffeine intoxicaiton >5-10g

  • can cause gran mal seizures

  • resp failure

  • death


16
New cards

caffeine withdrawal

  • prolonged daily use

  • abrupt cessation of or reduction in caffeine use followed within 24hr by 3+ of followign

    • HA- fatigue, dysmorphic mood, depressed, mood, or irritatbility; difficulty concentrating; flu like sx

  • onset 12-24hrs after last dose

  • resolves within 1 week

  • taper use instead to stopping abruptly


17
New cards

leading preventable cause of death

tobacco

18
New cards

tobacco neuropharm

  • psychoactive component of tobacco is nicotine

  • affects CNS by acting a an agonist to nicotoinic ACh receptors

    • reaches brain within 15sec

    • half life of nicotine is 2hrs

  • highly addictive- affects dopaminergic system

  • increased circulating norepi adn epi

  • increased release of vasopressin, beta- endoprhin, ACTH, adn cortisol, contribute to basic stimulatory effects


19
New cards

tobacco tolerance

  • disappearance tolerance: disappearance of nausea and dizziness after intake, more intense effect first use of the day


20
New cards

tobacco use disorder associated fts:

smokign within 30min of waking, smoking daily, increased number cig/day, and wakign at night to smoke

21
New cards

tobacco withdrawal criterion

  • daily use for at least several weeks

  • abrupt cessation of tobacco use, or reduction in amnt used followed within 24hrs of 4+:

    • irritability, frsustration,anger

    • anxierty

    • difficulty concentrating

    • increased appetite

    • restlessness

    • depressed mood

    • insomnia

  • can dev within 2 hrs of smokign last cig

  • peak in the first 24hrs to 48hrs and can last for weeks or months


22
New cards

other common sx of tobacco withdrawal

  • intesnse ccraving

  • drowsiness adn paradoxical trouble sleeping

  • decreased HR adn BP

  • decreased motor performance

  • increased muscle tension


23
New cards

tobacco use disorder tx- ready to quit

  • cmbine pharmacotherapy + behavioral support

  • first line med

    • varenciline

    • NRT

    • buproprion

  • behavioral interventions

    • brief counseling and motivational support

    • quitline referral

    • follow up 1-4weeks to assess adherence, SE, and response; reinfornce positice behavioral changes


24
New cards

varenicline

  • most effective singel modification

  • reduced cravings and nicotien reward


25
New cards

NRT

  • nicotine replacement therapy: combine short and long acting products (patch + gum/.lozenges)


26
New cards

tobacco use disorder-not ready to quit

  • motivational interviewing

  • reduce to quit strategy

    • set achieveable reduction oals

    • consider NRT or varenicline before quit date

  • continue engagements

    • offer follow up adn reasses readiness

    • avoid judgement or pressure


27
New cards

EVALI

  • acute lung injury associated with vaping

  • strongly linked to E acetate in THC containing prod


28
New cards

EVALI clinical pres

  • respiratory: dough, dyspnea, chest pain

  • GI: n/v/d, abd pain

  • constitutional: fever, chills, fatiguge; hypoxemia, tachy, adn tachypnea


29
New cards

EVALI dx

  • recent vaping exposure (within 90 days)

  • pulm infiltrates; eval for infection adn alternative dx


30
New cards

EVALI imaging

  • bilateral infiltrates on CXR or groufn glass opactities on CT


31
New cards

EVALI tx

  • stop vaping

  • supportive care and supp O2

  • consider systemic corticosteroids in selected cases after eval of infection

  • hosp is SpO2 <95% on RA, resp distress, ot sig comorbidities


32
New cards

cannabis use clinical fts

  • MC physical effects: dilation of conjunctival vessels and mild tachy

  • sx of acute intoxication are dose dependent adn include

    • tachy, BP changes, conjunctival injection, dry mouth, slowed or slurred speech, and ataxia

    • sedation and increased appetite

    • psych euphoria adn relaxaation

  • may cause acute depressionm anxiety, perceptual dist, transient paranoia

  • neuropsych impairement, esp attention, concentration, episodic memory, and associative learning

  • risk of death due to toxicity is neg

    • can be fatal due to taruamatic physical inury, or cardiac patho


33
New cards

cannabis comorbidities and adverse effects

  • substantial bidirectional comorbidity btwn cannabis use and psych disorders

  • use linked to decreased in goal directed activity adn decreased self efficacy known as amotivational syndrome → poor school/work performance

  • may be associated with higher a long term mortality rate: largely associated with accidents, suicide, and cardiopulm cond

  • cong function even while unintoxicated may become compromised, contributing to difficulty at school/work


34
New cards

adverse systemic effects of cannabis use

  • pulm and cards effects

  • hyper emesis syndrome

  • nonsemonima testicular cancer

  • association with cancer unclear

  • chronic use

    • esp in adolescence, assoicated with dev schizophrenia


35
New cards

cannabis intoxication

  • recent use

  • clinically sig problematic behavioral or psych changes (Impaired motor coordination, euphoria, anxiety, sensation of slowed time, impaired judegement, social withdrawal) tht dev due to use

  • ≥2:

    • conj injection

    • increased appettite

    • dry mouth

    • tachy in high doses, iuses may experience depersonalization and derealizaiton


36
New cards

cannabis withdrawal

  • cessation of use that was heavy and prolonged

  • ≥3 1week after d/c

    • irritablity, anger, aggression

    • nervousness or anxirty

    • sleep difficulty

    • decreased appetite or weight loss

    • restlessness

    • depressed mood

    • 1+ physical sx causing discomfort


37
New cards

when is cannabis drug testing useful

  • when resuls help eval AMS, psychosis, co exposures

  • when relevent to DDx,

  • when required monitoring ot occupationa/legal purposes, with appropriate consent


38
New cards

drug test detection- single/occasional use

  • 1-3days


39
New cards

drug test detection- moderate use

  • 3-7 days


40
New cards

drug test detection- frequent/daily use

  • 10-15 days


41
New cards

drug test detection- heavy chronic use

  • 30+ days,


42
New cards

cannabis use disorder tx- brief intevention

  • pt centeres

  • nonjudgemental counseling


43
New cards

cannabis use disorder tx- psychosocial intervention

  • cog behavioral thearpy (CBT) and or motivational enhancement therapy


44
New cards

cannabis use disorder tx- addiction counseling and mutual help groups

marj ananymous

45
New cards

cannabis use disorder tx- med

  • limited benefit in reducign use

  • none are FDA approved


46
New cards

inhalants

  • volatile substances that produce rapid feeligns of euphoria and inebriation due to rapid absorption through pulm vascular bed


47
New cards

inhalants- clinical manifestations

  • often undetected

  • clues: chemical odor of breath, skin or clothes; empty solvent containers or bags, rags, ot gauze in possession or trash

    • huffer orglue sniffer rash: eczematoid dermatitis with erythema and pruritus in the peroral area, may extend to midface


48
New cards

inhalant intoxicaiton

  • rcent intended ot unintended short-term , high dise exposure to inhalant substances, including voaltile hydrocarbons such as toluene gasoline

  • clinically sig problematic behavioral or psych changes

  • 2+

    • dizziness; nystagmus; incoordination; slurred speech; unsteady gait; laethargy; depressed reflexes; paychomotor retardation; tremor; generalized muscle weakness; blurred viison or diplopia

  • RARE


49
New cards

inhalant use eval

  • rapid bloos glucose

  • pulse ox

  • ECG an dcontinuous cardiac monitoring for arrythmias

  • urine drug screen


50
New cards

additional test if sus chronic inhalant misuse

  • methemeglobin level if nitrite misuse (very dark/chocolate brown venous blood or cyanosis even with O2)

  • venous blood lead if leaded gasoline misuse sus

  • CXR if hypoxemia, crackles,o rresp


51
New cards

inhalaatn use disorder tx- supportive care

  • supp 100% O2 by nonrebreather face mask for hypoxia


52
New cards

inhalant use disorder tx- antidotes

  • sepcific to exposure

    • methemaglobinemia caused by nitrite exposure (high dose oxygen + IV methylene blue)

    • llead toxicity (chelation)

    • nitrous oxide neurotox (vit B12)


53
New cards

inhalant use disorder tx- psych care

  • referral fro SUD tx adn or for formal detox

  • polydrug use an coexisting psychopathology are common

  • residentaial tx may improve outcome


54
New cards

stimulants

  • type so fpsychoactive substances that increase activity in rhe brain an dcan temp elevate alertness, mood, and awareness

    • amphetamine type substances usually taken orally, o rIV, methampheatomine also takedn intranasal

    • may be obtained by by Rx for tx of obesity, ADHD, and narcolepsy and diverted to illegal market

    • cocain powder ususalluy snorted or dissolved


55
New cards

stimulants- amphetamines neurophaarm

  • produce effects by releasing catecholamines, esp dopamine

  • newer cause mor release of norepi adn seritonin

  • tolerance dev, less addictive than cocaine


56
New cards

stimulants- cocaine neuropharm

  • behavioral effect is competitive blockade of dopamine reuptake

  • powergul addictive qualities

  • tolerance and psych dependence dev

  • physiological dependence occurs, withdrawal is usually mild


57
New cards

stimulant use- clinical manifestations

  • geenral- WL and malnutrition

  • dermatologic- skin sores adn excoriations, tracks

  • ENT- sinusitis, epistaaxis, performated nasal spetum, peridontal disease

  • resp- coughing, bronchitis, pneumonitis, pulm edema, resp distress, pneumothroax, pulm arterial HTN

  • CV- HTN, tachy, arrhytmias, and MI

  • neuro- seizures, HA, CVA, ICH, cog impairment

  • psych- impulsivity, anxiety, agitaiton, hallucinations, mood disturbacne, psychosis, paranoia

  • increased risk HIV and hep C with IVDU adn high risk sexual acitivty


58
New cards

stimulant intoxication

  • recent use of amphetamine type substanc, cocaine, or other stim

  • clinically sig problematic behavioral or psych changes that dev due to use

  • 2+

    • tahcy or brady; ppupillary dialtion; hypo/.HTN; perspiration or chills; n/v; WL; depression, chest pain or cardiac arrhtymias


59
New cards

stimulant withdrawal

  • cessation or reduction in prolonged stimulant use

  • dysphoric mood and 2+ of following changes due to cesation

    • fatigue, vivid unpleasant dreams; insomniapr hypersomnia; increased appetite; psychomotor retardation or agitation


60
New cards

acute stimulant intoxication can cause

  • agitaiton

  • paranoia/psychosis

  • hyperthermia

  • tachy/HTN

  • ches pain/MI

  • arrhtyhmia

  • seizure

  • stroke


61
New cards

initial tx of acute stimulant intoxicaiton

  • supportive care

  • benzo for severe agitation/sympathetic sxcess

  • emergency eval for chest pain. hyperthermia, severe HTN, neuro findings


62
New cards

urien drug testing- cocaine

  • 2-3days, 7 days with heavy use

  • detects metabolite- benzolycgonine; one of the most accutare DOA screenign

  • fals pos with coca tea, coca leaves


63
New cards

urine drug test- amphetamine/methamphetamine/MDMA/MDA/MDEA

  • 1-2days, 2-4days with heavy use

  • numerous potential for false pos


64
New cards

urine drug testing- methylphenidate

  • not detected via amphetamine assay, needs targeted analysis


65
New cards

stimulant use disorder tx- psychosocial intervention

  • mild- indiviudal or gorup counseling; if no abstinence after 3 weeks transition to intensive outpt tx combined with contingency mgmt

  • mod- intensive outpt program combined with contingency mgmt and motivational interviewing

  • subsequent tx- for indiv who respond to psychosocial tx, cont tx fro up to one year; return to tx for return to use


66
New cards

stimulant use disorder- suboptimal response after 8-12weeks

  • consider pharm augmentation

  • cocaine use- topiramate first choice; then long acting amphetamines, then combo

  • methmphetamine use- comboof naltrexone and bupropion as the first choice; mirtazapien adn methylphenidate are aother tx options